<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101686</url>
  </required_header>
  <id_info>
    <org_study_id>CPTAIV-0020-411</org_study_id>
    <secondary_id>A5961021</secondary_id>
    <nct_id>NCT00101686</nct_id>
  </id_info>
  <brief_title>Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.</brief_title>
  <official_title>A Randomized, Multi-Center Phase III Trial Of Irinotecan In Combination With Three Different Methods Of Administration Of Fluoropyrimidine: Infusional 5-FU (FOLFIRI), Modified-Bolus 5-FU (Day 1 &amp; 8), And Oral Capecitabine (Day 1-14); With Celecoxib Versus Placebo As First-Line Treatment For Patients With Metastatic Colorectal Cancer Study Amended April 23, 2004 To Include Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares in the first study period combination of Irinotecan with three different
      methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral). In the second
      period of study it compares FOLFIRI [a chemotherapy regime that combines bolus irinotecan and
      leucovorin [LV] with infusional 5-fluorouracil (5-FU)] + bevacizumab and mlFL + bevacizumab.
      Measures of efficacy and safety will be reported.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL</measure>
    <time_frame>every 6 weeks until disease progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression: FOLFIRI, mIFL and CapeIRI</measure>
    <time_frame>every 6 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response: FOLFIRI, mIFL and CapeIRI</measure>
    <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time: FOLFIRI, mIFL and CapeIRI</measure>
    <time_frame>assessed at least every week during treatment and at least every 3 months during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Survival: FOLFIRI, mIFL and CapeIRI</measure>
    <time_frame>1 year from date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression : Celecoxib and Placebo</measure>
    <time_frame>every 6 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response: Celecoxib and Placebo</measure>
    <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time: Celecoxib and Placebo</measure>
    <time_frame>assessed at least every week during treatment and at least every 3 months during follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression: Bevacizumab With FOLFIRI, mIFL</measure>
    <time_frame>every 6 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response: Bevacizumab With FOLFIRI, mIFL</measure>
    <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Survival: Bevacizumab With FOLFIRI, mIFL</measure>
    <time_frame>1 year from date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Time at Last Follow-Up Visit: Bevacizumab With FOLFIRI, mIFL</measure>
    <time_frame>Last Follow-Up Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose Reduction Due to Treatment Emergent Adverse Events</measure>
    <time_frame>Day 1; Day 8; and at end of every 3 treatment cycles for FOLFIRI; end of every 2 cycles for mIRI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Relative Dose Intensity of Irinotecan</measure>
    <time_frame>End of treatment cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">547</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Modified Bolus 5-FU/LV with Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>miFL + bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Infusional 5-FU/LV with Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Capecitabine with Irinotecan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified Bolus 5-FU/LV with Irinotecan</intervention_name>
    <description>Day 1 &amp; 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID [two times a day] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).</description>
    <arm_group_label>Modified Bolus 5-FU/LV with Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI + bevacizumab</intervention_name>
    <description>Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks
Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID [two times a day] oral Every 2 weeks</description>
    <arm_group_label>FOLFIRI + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miFL + bevacizumab</intervention_name>
    <description>Day 1 Bevacizumab 7.5mg/kg IV *over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID [two times a day] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID [two times a day] continues daily without interruption Every 3 weeks</description>
    <arm_group_label>miFL + bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infusional 5-FU/LV with Irinotecan</intervention_name>
    <description>Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID [two times a day](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).</description>
    <arm_group_label>Infusional 5-FU/LV with Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Capecitabine with Irinotecan</intervention_name>
    <description>Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID [two times a day] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).</description>
    <arm_group_label>Oral Capecitabine with Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with
             evidence of metastatic disease. (Stage IV distant disease)

          -  Present or past histological documentation of adenocarcinoma of the colon or rectum.
             The site of the primary lesion must be or have been confirmed endoscopically,
             radiologically, or surgically to be or have been in the large bowel. Patients with a
             history of colorectal cancer treated by surgical resection who develop radiological or
             clinical evidence of metastatic cancer do not require separate histological or
             cytological confirmation of metastatic disease unless:

          -  An interval of greater than five years has elapsed between the primary surgery and the
             development of metastatic disease.

          -  The primary cancer was a Duke's A or B1.

          -  Physicians should consider biopsy of lesions to establish the diagnosis of metastatic
             colorectal cancer in each case if there is substantial clinical ambiguity regarding
             the nature of source of apparent metastases.

        Exclusion Criteria:

          -  Patients who received any prior systemic anticancer therapy for metastatic colorectal
             cancer (e.g., chemotherapy, antibody therapy, immunotherapy, gene therapy, vaccine
             therapy, cytokine therapy, or other experimental agents).

          -  Patients cannot have concurrent malignancies at study entry.

          -  Exceptions: Patients with prior non-colorectal malignancies will be eligible if they
             have been disease-free for Â³ 3 years or are deemed at low risk for recurrence by their
             treating physician (e.g., early stage prostate cancer, melanoma or bladder cancer).
             Patients with squamous or basal cell carcinoma of the skin or in situ cervical cancer
             that have been effectively treated are eligible, even if these were diagnosed within 3
             years before randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmgingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmngham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hot Spring</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72764</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arroyo Grande</city>
        <state>California</state>
        <zip>93420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fountian Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902-3628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61108-2472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <zip>46038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shrevport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Manhaset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28302-2000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bartlesville</city>
        <state>Oklahoma</state>
        <zip>74006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606-5208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702-1449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230-2510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fredericksburg</city>
        <state>Texas</state>
        <zip>78624-3847</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <zip>75042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061-224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090-0504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lacy</city>
        <state>Washington</state>
        <zip>98503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V76</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1P 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6W 3X4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7A 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 4B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Auckland</city>
        <zip>1</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <zip>9001</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Riccarton</city>
        <zip>8020</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wellington</city>
        <zip>6039</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2005</study_first_submitted>
  <study_first_submitted_qc>January 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2005</study_first_posted>
  <results_first_submitted>October 20, 2009</results_first_submitted>
  <results_first_submitted_qc>October 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2009</results_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FOLFIRI + Celecoxib</title>
          <description>Irinotecan plus infusional 5-Fluorouracil(5-FU)/Leucovorin(LV) (FOLFIRI) with celecoxib</description>
        </group>
        <group group_id="P2">
          <title>FOLFIRI + Placebo</title>
          <description>Irinotecan plus infusional 5-FU/LV (FOLFIRI) with placebo</description>
        </group>
        <group group_id="P3">
          <title>mIFL + Celecoxib</title>
          <description>Modified irinotecan plus bolus 5-FU/LV (mIFL) with celecoxib</description>
        </group>
        <group group_id="P4">
          <title>mIFL + Placebo</title>
          <description>Modified irinotecan plus bolus 5-FU/LV (mIFL) with placebo</description>
        </group>
        <group group_id="P5">
          <title>CapeIRI + Celecoxib</title>
          <description>Irinotecan plus capecitabine (CapeIRI) with celecoxib</description>
        </group>
        <group group_id="P6">
          <title>CapeIRI + Placebo</title>
          <description>Irinotecan plus capecitabine (CapeIRI) with placebo</description>
        </group>
        <group group_id="P7">
          <title>Bevacizumab + FOLFIRI + Celecoxib</title>
          <description>Bevacizumab + Irinotecan plus infusional 5-FU/LV (FOLFIRI) with celecoxib</description>
        </group>
        <group group_id="P8">
          <title>Bevacizumab + FOLFIRI + Placebo</title>
          <description>Bevacizumab + Irinotecan plus infusional 5-FU/LV (FOLFIRI) with placebo</description>
        </group>
        <group group_id="P9">
          <title>Bevacizumab + mIFL + Celecoxib</title>
          <description>Bevacizumab + Modified irinotecan plus bolus 5-FU/LV (mIFL) with celecoxib</description>
        </group>
        <group group_id="P10">
          <title>Bevacizumab + mIFL + Placebo</title>
          <description>Bevacizumab + Modified irinotecan plus bolus 5-FU/LV (mIFL)with placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="72"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="70"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="29"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P2" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P3" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P4" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P5" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P6" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P7" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P8" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P9" count="0">Patients treated until disease progression.</participants>
                <participants group_id="P10" count="0">Patients treated until disease progression.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="72"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>initiation other anti-cancer treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>&gt;3 week delay treatment due toxicity</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unacceptable toxicity</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but did not receive treament</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>intercurrent non-cancer related illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FOLFIRI + Celecoxib</title>
          <description>Irinotecan plus infusional 5-Fluorouracil(5-FU)/Leucovorin(LV) (FOLFIRI) with celecoxib</description>
        </group>
        <group group_id="B2">
          <title>FOLFIRI + Placebo</title>
          <description>Irinotecan plus infusional 5-FU/LV (FOLFIRI) with placebo</description>
        </group>
        <group group_id="B3">
          <title>mIFL + Celecoxib</title>
          <description>Modified irinotecan plus bolus 5-FU/LV (mIFL) with celecoxib</description>
        </group>
        <group group_id="B4">
          <title>mIFL + Placebo</title>
          <description>Modified irinotecan plus bolus 5-FU/LV (mIFL) with placebo</description>
        </group>
        <group group_id="B5">
          <title>CapeIRI + Celecoxib</title>
          <description>Irinotecan plus capecitabine (CapeIRI) with celecoxib</description>
        </group>
        <group group_id="B6">
          <title>CapeIRI + Placebo</title>
          <description>Irinotecan plus capecitabine (CapeIRI) with placebo</description>
        </group>
        <group group_id="B7">
          <title>Bevacizumab + FOLFIRI + Celecoxib</title>
          <description>Bevacizumab + Irinotecan plus infusional 5-FU/LV (FOLFIRI) with celecoxib</description>
        </group>
        <group group_id="B8">
          <title>Bevacizumab + FOLFIRI + Placebo</title>
          <description>Bevacizumab + Irinotecan plus infusional 5-FU/LV (FOLFIRI) with placebo</description>
        </group>
        <group group_id="B9">
          <title>Bevacizumab + mIFL + Celecoxib</title>
          <description>Bevacizumab + Modified irinotecan plus bolus 5-FU/LV (mIFL) with celecoxib</description>
        </group>
        <group group_id="B10">
          <title>Bevacizumab + mIFL + Placebo</title>
          <description>Bevacizumab + Modified irinotecan plus bolus 5-FU/LV (mIFL)with placebo</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="73"/>
            <count group_id="B6" value="72"/>
            <count group_id="B7" value="27"/>
            <count group_id="B8" value="30"/>
            <count group_id="B9" value="30"/>
            <count group_id="B10" value="30"/>
            <count group_id="B11" value="547"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" lower_limit="35.0" upper_limit="81.0"/>
                    <measurement group_id="B2" value="62.0" lower_limit="31.0" upper_limit="87.0"/>
                    <measurement group_id="B3" value="61.0" lower_limit="34.0" upper_limit="78.0"/>
                    <measurement group_id="B4" value="62.0" lower_limit="29.0" upper_limit="80.0"/>
                    <measurement group_id="B5" value="62.0" lower_limit="20.0" upper_limit="78.0"/>
                    <measurement group_id="B6" value="62.5" lower_limit="33.0" upper_limit="85.0"/>
                    <measurement group_id="B7" value="59.0" lower_limit="37.0" upper_limit="81.0"/>
                    <measurement group_id="B8" value="59.5" lower_limit="32.0" upper_limit="80.0"/>
                    <measurement group_id="B9" value="61.0" lower_limit="45.0" upper_limit="84.0"/>
                    <measurement group_id="B10" value="59.0" lower_limit="35.0" upper_limit="84.0"/>
                    <measurement group_id="B11" value="61.0" lower_limit="20.0" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL</title>
        <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
        <time_frame>every 6 weeks until disease progression</time_frame>
        <population>Intent-to-Treat Population (ITT) - all subjects who were randomized, with study drug assignment designated according to initial randomization, regardless of whether subjects received any study drug or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL</title>
          <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
          <population>Intent-to-Treat Population (ITT) - all subjects who were randomized, with study drug assignment designated according to initial randomization, regardless of whether subjects received any study drug or received a different drug from that to which they were randomized.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" lower_limit="7.43" upper_limit="8.97"/>
                    <measurement group_id="O2" value="6.01" lower_limit="5.52" upper_limit="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <p_value_desc>p-value corresponds to the log-rank test for comparing Kaplan-Meier survival curves.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.433</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>Hazard ratio [mIRI:FOLFIRI] is from the Cox Proportional Hazard Model using treatment (FOLFIRI, mIRI, CapeIRI), age (&lt;=70 vs &gt;70), performance status (0 vs 1), aspirin (Yes vs No), celecoxib (Yes or No) as the covariates.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression: FOLFIRI, mIFL and CapeIRI</title>
        <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
        <time_frame>every 6 weeks until disease progression</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression: FOLFIRI, mIFL and CapeIRI</title>
          <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
          <population>ITT Population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" lower_limit="7.06" upper_limit="8.71"/>
                    <measurement group_id="O2" value="5.98" lower_limit="5.45" upper_limit="6.9"/>
                    <measurement group_id="O3" value="5.82" lower_limit="4.60" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0042</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.512</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0156</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.368</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4659</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response: FOLFIRI, mIFL and CapeIRI</title>
        <description>A subject will be considered achieving an overall response if the subject has a sustained Complete Response (CR) or Partial Response (PR) for at least 4 weeks, confirmed by tumor assessments. (CR: Disappearance of all target lesions. PR: greater than or equal to 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the Pre-treatment sum LD. )</description>
        <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response: FOLFIRI, mIFL and CapeIRI</title>
          <description>A subject will be considered achieving an overall response if the subject has a sustained Complete Response (CR) or Partial Response (PR) for at least 4 weeks, confirmed by tumor assessments. (CR: Disappearance of all target lesions. PR: greater than or equal to 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the Pre-treatment sum LD. )</description>
          <population>ITT Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>47.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>38.85</ci_lower_limit>
            <ci_upper_limit>55.71</ci_upper_limit>
            <estimate_desc>Exact confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>43.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>34.95</ci_lower_limit>
            <ci_upper_limit>51.86</ci_upper_limit>
            <estimate_desc>Exact confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>38.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>30.66</ci_lower_limit>
            <ci_upper_limit>47.06</ci_upper_limit>
            <estimate_desc>Exact confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4751</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1591</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4395</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Time: FOLFIRI, mIFL and CapeIRI</title>
        <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
        <time_frame>assessed at least every week during treatment and at least every 3 months during follow-up</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Time: FOLFIRI, mIFL and CapeIRI</title>
          <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
          <population>ITT Population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.06" lower_limit="17.87" upper_limit="26.55"/>
                    <measurement group_id="O2" value="17.64" lower_limit="14.29" upper_limit="23.03"/>
                    <measurement group_id="O3" value="18.92" lower_limit="15.74" upper_limit="23.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0879</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.268</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2765</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9364</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Survival: FOLFIRI, mIFL and CapeIRI</title>
        <description>Number of patients alive or dead at 1 year. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
        <time_frame>1 year from date of randomization</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Survival: FOLFIRI, mIFL and CapeIRI</title>
          <description>Number of patients alive or dead at 1 year. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
          <population>ITT Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression : Celecoxib and Placebo</title>
        <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
        <time_frame>every 6 weeks until disease progression</time_frame>
        <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All patients treated with celecoxib: combined patients treated with FOLFIRI+ celecoxib, mIRI+ celecoxib, CapeIRI+ celecoxib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients treated with placebo: combined patients treated with FOLFIRI+placebo, mIRI+placebo, CapeIRI+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression : Celecoxib and Placebo</title>
          <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
          <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.64" lower_limit="5.68" upper_limit="7.39"/>
                    <measurement group_id="O2" value="6.70" lower_limit="6.01" upper_limit="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7163</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response: Celecoxib and Placebo</title>
        <description>A subject will be considered achieving an overall response if the subject has a sustained CR or PR for at least 4 weeks, confirmed by tumor assessments. (Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): â¥ 30% decrease in the sum of the LD of target lesions, taking as reference the Pre-treatment sum LD. )</description>
        <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
        <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All patients treated with celecoxib: combined patients treated with FOLFIRI+ celecoxib, mIRI+ celecoxib, CapeIRI+ celecoxib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients treated with placebo: combined patients treated with FOLFIRI+placebo, mIRI+placebo, CapeIRI+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response: Celecoxib and Placebo</title>
          <description>A subject will be considered achieving an overall response if the subject has a sustained CR or PR for at least 4 weeks, confirmed by tumor assessments. (Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): â¥ 30% decrease in the sum of the LD of target lesions, taking as reference the Pre-treatment sum LD. )</description>
          <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>39.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>32.83</ci_lower_limit>
            <ci_upper_limit>46.34</ci_upper_limit>
            <estimate_desc>confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>46.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>39.76</ci_lower_limit>
            <ci_upper_limit>53.42</ci_upper_limit>
            <estimate_desc>confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1559</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Time: Celecoxib and Placebo</title>
        <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
        <time_frame>assessed at least every week during treatment and at least every 3 months during follow-up</time_frame>
        <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All patients treated with celecoxib: combined patients treated with FOLFIRI+ celecoxib, mIRI+ celecoxib, CapeIRI+ celecoxib</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients treated with placebo: combined patients treated with FOLFIRI+placebo, mIRI+placebo, CapeIRI+placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Time: Celecoxib and Placebo</title>
          <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
          <population>ITT Population. Celecoxib participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab); Placebo participants were combined from FOLFIRI, mIRI, and Capecitabine treatments (not bevacizumab).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.06" lower_limit="16.92" upper_limit="24.28"/>
                    <measurement group_id="O2" value="18.83" lower_limit="16.26" upper_limit="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5316</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.080</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression: Bevacizumab With FOLFIRI, mIFL</title>
        <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
        <time_frame>every 6 weeks until disease progression</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + mIFL</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression: Bevacizumab With FOLFIRI, mIFL</title>
          <description>Time to disease progression is defined as the number of months from date of randomization to the date of first documentation of disease progression (PD).</description>
          <population>ITT population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.17" lower_limit="9.00" upper_limit="17.41"/>
                    <measurement group_id="O2" value="8.31" lower_limit="6.31" upper_limit="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2835</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response: Bevacizumab With FOLFIRI, mIFL</title>
        <description>A subject will be considered achieving an overall response if the subject has a sustained CR or PR for at least 4 weeks, confirmed by tumor assessments. (Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): â¥ 30% decrease in the sum of the LD of target lesions, taking as reference the Pre-treatment sum LD. )</description>
        <time_frame>every 6 weeks during chemotherapy until disease progression</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + mIFL</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response: Bevacizumab With FOLFIRI, mIFL</title>
          <description>A subject will be considered achieving an overall response if the subject has a sustained CR or PR for at least 4 weeks, confirmed by tumor assessments. (Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): â¥ 30% decrease in the sum of the LD of target lesions, taking as reference the Pre-treatment sum LD. )</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>57.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>44.08</ci_lower_limit>
            <ci_upper_limit>70.86</ci_upper_limit>
            <estimate_desc>Exact confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>F-distribution method</param_type>
            <param_value>53.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.00</ci_lower_limit>
            <ci_upper_limit>66.33</ci_upper_limit>
            <estimate_desc>Exact confidence interval for binomial proportion using the F-distribution method (unit: %)</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7388</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Survival: Bevacizumab With FOLFIRI, mIFL</title>
        <description>Number of patients alive or dead at 1 year. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
        <time_frame>1 year from date of randomization</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + mIRI</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Survival: Bevacizumab With FOLFIRI, mIFL</title>
          <description>Number of patients alive or dead at 1 year. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive.</description>
          <population>ITT Population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alive at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dead at 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Censored</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Time at Last Follow-Up Visit: Bevacizumab With FOLFIRI, mIFL</title>
        <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive. Zero subjects analyzed indicates median could not be analyzed based on number of subjects who died.</description>
        <time_frame>Last Follow-Up Visit</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab + mIRI</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Time at Last Follow-Up Visit: Bevacizumab With FOLFIRI, mIFL</title>
          <description>Survival time defined as time from date of randomization to date of death. In the absence of confirmation of death, survival time was censored to last date the subject known to be alive. Zero subjects analyzed indicates median could not be analyzed based on number of subjects who died.</description>
          <population>ITT Population.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.99" lower_limit="23.82" upper_limit="34.76"/>
                    <measurement group_id="O2" value="19.22" lower_limit="11.60" upper_limit="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0370</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.794</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose Reduction Due to Treatment Emergent Adverse Events</title>
        <description>Number of subjects that had at least one Treatment-Emergent Adverse Event (TEAE) that led to a dose reduction. TEAE includes all reported Adverse Events that occurred within 30 days of last study medication.</description>
        <time_frame>Day 1; Day 8; and at end of every 3 treatment cycles for FOLFIRI; end of every 2 cycles for mIRI</time_frame>
        <population>As-Treated population - all subjects who received any study medication, with treatment assignments designated according to actual study treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
          <group group_id="O4">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O5">
            <title>Bevacizumab + mIRI</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Reduction Due to Treatment Emergent Adverse Events</title>
          <description>Number of subjects that had at least one Treatment-Emergent Adverse Event (TEAE) that led to a dose reduction. TEAE includes all reported Adverse Events that occurred within 30 days of last study medication.</description>
          <population>As-Treated population - all subjects who received any study medication, with treatment assignments designated according to actual study treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Relative Dose Intensity of Irinotecan</title>
        <description>Relative dose intensity for a cycle was calculated as the percentage of the actual dose intensity of the cycle divided by the planned dose intensity of the cycle. Overall relative dose intensity was calculated as the average relative dose intensities over all cycles. (Dose intensity for each cycle was calculated as the actual dose level of the study medication received in that cycle divided by the number of weeks in the cycle.)</description>
        <time_frame>End of treatment cycle</time_frame>
        <population>As-Treated population</population>
        <group_list>
          <group group_id="O1">
            <title>FOLFIRI</title>
            <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O2">
            <title>mIFL</title>
            <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
          </group>
          <group group_id="O3">
            <title>CapeIRI</title>
            <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
          </group>
          <group group_id="O4">
            <title>Bevacizumab + FOLFIRI</title>
            <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
          </group>
          <group group_id="O5">
            <title>Bevacizumab + mIRI</title>
            <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Relative Dose Intensity of Irinotecan</title>
          <description>Relative dose intensity for a cycle was calculated as the percentage of the actual dose intensity of the cycle divided by the planned dose intensity of the cycle. Overall relative dose intensity was calculated as the average relative dose intensities over all cycles. (Dose intensity for each cycle was calculated as the actual dose level of the study medication received in that cycle divided by the number of weeks in the cycle.)</description>
          <population>As-Treated population</population>
          <units>percent dose intensity</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="145"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" spread="0.6"/>
                    <measurement group_id="O2" value="94.5" spread="0.6"/>
                    <measurement group_id="O3" value="93.8" spread="0.7"/>
                    <measurement group_id="O4" value="93.3" spread="0.8"/>
                    <measurement group_id="O5" value="95.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FOLFIRI</title>
          <description>Irinotecan + infusional 5-FU/LV with celecoxib or placebo</description>
        </group>
        <group group_id="E2">
          <title>mIFL</title>
          <description>Irinotecan + modified-bolus 5-FU/LV with celecoxib or placebo</description>
        </group>
        <group group_id="E3">
          <title>CapeIRI</title>
          <description>Irinotecan + oral capecitabine with celecoxib or placebo</description>
        </group>
        <group group_id="E4">
          <title>Bevacizumab + FOLFIRI</title>
          <description>Bevacizumab + Irinotecan + infusional 5-FU/LV with (celecoxib or placebo)</description>
        </group>
        <group group_id="E5">
          <title>Bevacizumab + mIRI</title>
          <description>Bevacizumab + Irinotecan + modified-bolus 5-FU/LV with (celecoxib or placebo)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arteriospasm coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrointestinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gallbladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Polytraumatism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Culture stool positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Renal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.9</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="108" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Procedural site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

